Martin Shkreli: Big Pharma's Blind Spot, Betting Against Quantum & What Prison Taught Him

Quantum Computing: A "Fraud" [00:01:18]

• Shkreli posits that quantum computing is a "fraud" or "fugazi," a "disgraciad," primarily because its advantages are limited to very specific algorithms.
• He explains that while quantum computers can perform tasks like integer factorization in polynomial time, which is remarkable to a "nerd," it offers little to business unless they are in the business of factoring numbers.
• Modern quantum computers are slow, single-core, and single-threaded, unable to compete with GPUs for general tasks like sorting.

  "But to a business person, unless you were in the business of factoring numbers, there's not a whole lot to be excited about here."

The Limitations of Quantum Technology [00:02:15]

• Shkreli argues that quantum computers lack storage, with no such thing as quantum RAM, forcing problems to have very small inputs.
• He notes that companies like Google and IBM, despite spending hundreds of millions on quantum research, have very few functional machines, unable to even multiply 300 by 200.
• Shkreli reveals he has been shorting quantum computing companies, losing millions but gaining "billions in insight."

  "Chelsea and I have tried every single quantum computer, quantum computer in the world. We cannot multiply 300 by 200 on any of these."

The Rise of Photonic Computing [00:04:05]

• Shkreli identifies photonic computing as the true future, predicting that current technologies like NVIDIA's H-100s will be obsolete in 20 years.
• He highlights startups like Neurofos, OptiCore, and Lumai that are developing photonic matmul cores, which could significantly outperform NVIDIA's offerings.
• The core advantage of photonic computing lies in its ability to perform matrix multiplications (matmul) almost instantaneously.

  "And what I saw in the corner of my eye was that matmuls in light are free. Yeah. They happen in instant time, which is a really remarkable thing."

Early Career and Drug Development [00:06:15]

• Shkreli began his career at 16 at Jim Cramer's hedge fund, learning about trading and investing.
• He transitioned to entrepreneurship and private equity, identifying inefficiencies in the pharmaceutical market where drug rights could be acquired cheaply and then productized and priced higher.
• He founded a natural language processing (NLP) company to help vet drug assets by reading scientific papers and patents.

  "We found that the marketplace for molecules had huge amounts of alpha. Whereas the marketplace at public companies, we could buy a drug from, I bought a drug from Bristol Myers for $2 million. And that same company is public today. It's worth $6 billion."

The Daraprim Controversy and Business Strategy [00:08:00]

• Shkreli discusses his controversial acquisition of Daraprim and the subsequent price hike, framing it as a business strategy to target neglected diseases.
• He explains that he acquired a drug discovered by Bristol Myers for hypertension, a "dead, sleepy market," and refocused it on FSGS, a rare disease with no existing treatments, leading to FDA approval and blockbuster status.
• This strategy, he argues, provided a needed drug for 30,000 patients and was a "great way to make a billion dollars."

  "So you sort of try to angle it in a way that makes sense. And in that case, the drug got FDA approved."

Skepticism on AI and Drug Discovery [00:10:30]

• Shkreli expresses strong skepticism about the current hype surrounding AI, particularly its purported benefits for drug development.
• He believes AI does not significantly aid drug discovery, stating that despite having computers for a long time, including a Cray cluster, there's little AI can do to help.
• He predicts there won't be a single AI-relevant drug in the next 10 years and dismisses claims that AI will lead to mass unemployment within years.

  "I don't think there'll be a single AI relevant drug in the next 10 years. Um, AI does not help drug discovery."

Critique of Effective Altruism and "Fear Mongering" [00:12:00]

• Shkreli criticizes the "fear mongering" associated with AI and the effective altruism (EA) movement, calling it "even worse."
• He advocates for "effective accelerationism" (EAC), a philosophy of "move fast and break things," contrasting it with the cautious approach of EA proponents.
• He believes that nerds get carried away with AI's potential dangers, comparing it to software that, while important, is not the "end of the world."

  "I think the fear mongering is, is a little ridiculous and there'll be a time to panic. It's just not now."

Investment Philosophy and Market Timing [00:14:00]

• Shkreli describes his investment approach as "nimble," looking for specific high-alpha events and disruptions rather than competing with the market.
• He discusses the massive influx of venture capital into AI, interpreting it as VCs funneling LP money to buy tokens, creating a potential valuation trap.
• He believes companies like Meta, with their distribution and product execution (e.g., Muse), show resilience and product chops in the AI space.

  "I think that what you mentioned earlier, productivity, I mean, there is infinite demand for intelligence and infinite demand for work."

Reflections on Prison and Personal Growth [00:17:00]

• Shkreli reflects on his time in prison, acknowledging his fear of not being seen as a great trader as a detrimental fixation.
• He learned that despite differences in background and actions, humans share common bonds and desires, such as maintaining friendships and being good parents.
• He now sees himself as a "wonderful entrepreneur" and "startup guy," accepting that he wasn't the best hedge fund manager.

  "I had a hard time admitting I was not the best hetero manager in the world, but I was a wonderful entrepreneur. That simple refusal to admit that put me in prison."